Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.60 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | MGAM | O43451 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | SI | P14410 | 1/20 | 0.42 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.42 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.39 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 2/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22558046 | 0.77 | ATM (0.54) | ALDH1A1LMNAHCAR2TSHRMAPT | |
| SCHEMBL16316919 | 0.77 | ALDH1A1 (0.50) | ALDH1A1SOAT1LMNAHSD17B10ALOX15 | |
| SCHEMBL1332089 | 0.76 | — | — | |
| SCHEMBL3673 | 0.76 | — | — | |
| SCHEMBL1958756 | 0.76 | ALDH1A1 (1.00) | ALDH1A1SOAT1LMNAHSD17B10ALOX15 | |
| SCHEMBL5712009 | 0.76 | ALDH1A1 (0.30) | ALDH1A1 | |
| SCHEMBL22558087 | 0.75 | NAAA (0.50) | ALDH1A1LMNAHCAR2TSHRNPSR1 | |
| SCHEMBL7328511 | 0.75 | ALDH1A1 (0.38) | ALDH1A1SOAT1LMNAHSD17B10ALOX15 | |
| Methane SCHEMBL1901030 | 0.74 | — | — | |
| Water SCHEMBL22362219 | 0.74 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 281 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115611933-A | Process for preparing arginase inhibitors and synthetic intermediates thereof | 因赛特公司 | 2023-01-17 | — | — | CN | claimed |
| US-20200062785-A1 | NOVEL PROCESS FOR THE PREPARATION OF 4-[(1-HYDROXY-1,3-DIHYDRO-2,1-BENZOXABOROL-5-YL) OXY] BENZONITRILE (CRISABOROLE) | BIOPHORE INDIA PHARMACEUTICALS PVT. LTD., (IN) | 2020-02-27 | — | — | US | claimed |
| WO-2018207216-A1 | NOVEL PROCESS FOR THE PREPARATION OF 4-[(1-HYDROXY-1,3-DIHYDRO-2,1-BENZOXABOROL-5-YL) OXY] BENZONITRILE (CRISABOROLE) | BIOPHORE INDIA PHARMACEUTICALS PVT. LTD. (IN) | 2018-11-15 | — | — | WO | claimed |
| CN-101899026-B | Intermediates for the preparation of analogs of halichondrin B | 卫材R&D管理有限公司 | 2016-08-03 | — | — | CN | claimed |
| US-20260085078-A1 | NON-AQUEOUS SYNTHESIS OF SILYLCARBONATE SOLVENTS | UCHICAGO ARGONNE, LLC (US) | 2026-03-26 | — | — | US | disclosed |
| CN-118355117-A | Oligonucleotide compositions and methods thereof | 波涛生命科学有限公司 | 2024-07-16 | — | — | CN | disclosed |
| CN-111936487-B | Compounds for the treatment of kinase dependent disorders | 埃克塞里艾克西斯公司 | 2024-07-09 | — | — | CN | disclosed |
| CN-111936136-B | Novel imidazopyrimidine compounds and uses thereof | 儿童医学中心公司 | 2024-07-05 | — | — | CN | disclosed |
| CN-113710660-B | DOT1L degradation agent and application thereof | 达纳-法伯癌症研究公司 | 2024-07-02 | — | — | CN | disclosed |
| CN-112312909-B | Compounds for the treatment of kinase dependent disorders | 埃克塞里艾克西斯公司 | 2024-07-02 | — | — | CN | disclosed |
| CN-114736219-B | Antitumor compounds | 法马马有限公司 | 2024-06-07 | — | — | CN | disclosed |
| CN-114751920-B | Antitumor compounds | 法马马有限公司 | 2024-06-07 | — | — | CN | disclosed |
| WO-2009080769-A1 | ANTITUMORAL COMPOUNDS | PHARMA MAR, S.A. (ES) | 2009-07-02 | — | — | WO | disclosed |
| CN-101360513-A | Biodegradable and thermosensitive poly(organophosphazene) hydrogel, preparation method thereof and use thereof | KOREA INST SCI & TECH (KR) | 2009-02-04 | — | — | CN | disclosed |
| EP-1620110-A2 | IMMUNOMODULATOR PHOSPHONATE CONJUGATES | GILEAD SCIENCES, INC. (US) | 2006-02-01 | — | — | EP | disclosed |
| US-6943174-B2 | 6,5-Fused bicyclic heterocycles | WARNER-LAMBERT COMPANY (US) | 2005-09-13 | — | — | US | disclosed |
| WO-2004096236-A2 | IMMUNOMODULATOR PHOSPHONATE CONJUGATES | GILEAD SCIENCES, INC. (US) | 2004-11-11 | — | — | WO | disclosed |
| US-20040014759-A1 | 6,5-Fused bicyclic heterocycles | PICARD JOSEPH ARMAND (US) | 2004-01-22 | — | — | US | disclosed |
| EP-1294718-A2 | 6,5-FUSED BICYCLIC HETEROCYCLES | WARNER-LAMBERT COMPANY LLC (US) | 2003-03-26 | — | — | EP | disclosed |
| WO-2001096336-A2 | 6,5-FUSED BICYCLIC HETEROCYCLES | WARNER-LAMBERT COMPANY (US) | 2001-12-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040014759-A1 | 6,5-Fused bicyclic heterocycles | ALOX15, ALOX5, ALOX15B | ALDH1A1 522/4885SOAT1 367/4885LMNA 1925/4885 |
| US-20200062785-A1 | NOVEL PROCESS FOR THE PREPARATION OF 4-[(1-HYDROXY-1,3-DIHYDRO-2,1-BENZOXABOROL-5-YL) OXY] BENZONITRILE (CRISABOROLE) | CYP4B1, CYP8B1, CYP4X1 | ALDH1A1 1454/4885SOAT1 2367/4885LMNA 1971/4885 |
| US-20260085078-A1 | NON-AQUEOUS SYNTHESIS OF SILYLCARBONATE SOLVENTS | TRPV2, TRPV3, TRPM2 | ALDH1A1 3475/4885SOAT1 1203/4885LMNA 565/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.